
FDA Grants Patent Protection to HemiClor Formulation Through 2045
The U.S. Food and Drug Administration has listed U.S. Patent No. 12,667,554 B1 in the Orange Book, securing intellectual property rights for HemiClor’s proprietary 12.5 mg chlorthalidone formulation. This regulatory milestone protects the hypertension medication’s unique delivery technology until 2045, shielding it from generic competition for the next two decades.
























